Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:
”Cancer-associated thrombosis (CAT) remains one of the highest-risk VTE settings, where we constantly balance recurrent VTE prevention against bleeding risk.
API-CAT evaluated whether a reduced-dose apixaban strategy could maintain efficacy while improving safety during extended anticoagulation.
The trial showed that a lower dose of apixaban (2.5 mg BID) was non-inferior to the standard dose (5 mg BID) for preventing recurrent VTE in patients with active cancer, and it was associated with less bleeding.”
Read the full article here.
Article: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez et al., for the API-CAT Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 27, 2026, 01:31Alessio De Rose: Addressing Micronutrient Deficiencies in the Era of GLP-1 Receptor Agonists
-
Jun 27, 2026, 01:21Michelle Sámano Sánchez: Exploring Vitamin C as an Adjunct Therapy for Anemia in Hemodialysis
-
Jun 27, 2026, 01:08Ana Raquel Gotine: The First Pragmatic Clinical Trial on MNPs and Childhood Anemia in Mozambique
-
Jun 27, 2026, 00:56Sherif Badawy: Reflecting on My Time with ASH CRTI
-
Jun 27, 2026, 00:48Zain Khalpey: Why High quality CPR is Only Part of Successful Cardiac Arrest Management
-
Jun 26, 2026, 22:31Wendy Dusenbury: The New Issue of the Stroke Clinician is Now Live
-
Jun 26, 2026, 20:42Ed Watson: When It Happens to You, Stroke Becomes Personal, Immediate, and Life-Changing
-
Jun 26, 2026, 19:45Nathan Connell: Transforming Surgical Care with Tranexamic Acid
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?